TScan Therapeutics (TCRX) Other Accumulated Expenses (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Other Accumulated Expenses of $196000.0 for Q1 2026, little changed year-over-year from $196000.0 in Q1 2025, and little changed quarter-over-quarter from $196000.0 in Q4 2025.
TScan Therapeutics (TCRX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Other Accumulated Expenses for 7 consecutive years, with $196000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses changed 0.0% year-over-year to $196000.0; the TTM figure through Mar 2026 stood at $196000.0 (changed 0.0% YoY), while the FY2025 annual figure was $196000.0, up 157.89% from the prior year.
- Other Accumulated Expenses was little changed at $196000.0 in Q1 2026 per TCRX's latest filing, from $196000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.3 million in Q3 2022 and bottomed at $76000.0 in Q4 2024.
- Historically, Other Accumulated Expenses has averaged $358235.3 across 5 years, with a median of $248000.0 in 2024.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses jumped 175.32% — and 2024, when it sank 82.12%.
- TScan Therapeutics' Other Accumulated Expenses stood at $431000.0 in 2022, then decreased by 1.39% to $425000.0 in 2023, then tumbled by 82.12% to $76000.0 in 2024, then jumped by 157.89% to $196000.0 in 2025, then changed by 0.0% to $196000.0 in 2026.
- Business Quant data shows TCRX's Other Accumulated Expenses at $196000.0 in Q1 2026, $196000.0 in Q4 2025, and $189000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 190,000.00 |
| Mar 31, 2026 | 196,000.00 |
| Dec 31, 2025 | 196,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Jun 30, 2025 | 190,000.00 |
| Mar 31, 2025 | 196,000.00 |
| Dec 31, 2024 | 76,000.00 |
| Sep 30, 2024 | 248,000.00 |
| Jun 30, 2024 | 247,000.00 |
| Mar 31, 2024 | 256,000.00 |
| Dec 31, 2023 | 425,000.00 |
| Sep 30, 2023 | 428,000.00 |
| Jun 30, 2023 | 427,000.00 |
| Mar 31, 2023 | 435,000.00 |
| Dec 31, 2022 | 431,000.00 |
| Sep 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 701,000.00 |
| Mar 31, 2022 | 158,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 668,000.00 |